IGF1R and neoplasm: This is highly required especially because clinical responses to anti-IGF1R is observed in approximately 15% in ES, the tumor type with the best response to this targeted approach, while clinical response was registered in only a small (1–5%) but distinct proportion of patients with solid tumors (46, 47).